Bridgeway Capital Management’s Cyclerion Therapeutics CYCN Stock Holding History

Bridgeway Capital Management’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,750	Closed	-$49.9K	–	1398
2023 Q1	$49.9K	Hold	5,750	–	–	﹤0.01%	1311
2022 Q4	$75.5K	Hold	5,750	–	–	﹤0.01%	1256
2022 Q3	$99K	Hold	5,750	–	–	﹤0.01%	1270
2022 Q2	$63K	Hold	5,750	–	–	﹤0.01%	1271
2022 Q1	$128K	Buy	+5,750	New	+$139K	﹤0.01%	1238
2021 Q2	–	Sell	-5,980	Closed	-$334K	–	1349
2021 Q1	$334K	Buy	5,980 +1,900	+47%	+$143K	0.01%	1205
2020 Q4	$250K	Sell	4,080 -1,470	-26%	-$100K	0.01%	1162
2020 Q3	$675K	Buy	5,550 +2,500	+82%	+$286K	0.02%	794
2020 Q2	$361K	Buy	+3,050	New	+$255K	0.01%	973

Other funds holding CYCN

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bridgeway Capital Management's CYCN Position: Q2 2023 in Review

Bridgeway Capital Management sold out of Cyclerion Therapeutics (CYCN) in Q2 2023, closing a stake of 5,750 shares — an estimated $49.9K sold.

Bridgeway Capital Management first reported a position in CYCN in Q2 2020 and held it in 9 quarters. The position peaked at $675K in Q3 2020. 18 funds tracked by Wall St. Rank hold CYCN as of Q2 2023.

Bridgeway Capital Management reported no remaining Cyclerion Therapeutics position as of Q2 2023 after selling out during the quarter.
Bridgeway Capital Management sold 5,750 Cyclerion Therapeutics shares in Q2 2023, an estimated $49.9K.
Bridgeway Capital Management first reported a position in Cyclerion Therapeutics in Q2 2020 and held it in 9 quarters.
Bridgeway Capital Management's Cyclerion Therapeutics position peaked at $675K in Q3 2020.
18 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2023.

Based on Bridgeway Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.